Day 1

PARAMOUNT: Promising results of double action drug treatment for patients with heart failure and preserved ejection fraction .

solaci
solaci
385
0

Editorial Comment: This Phase II study included 149 patients following these criteria: NYHA II-IV heart failure, +40 yr, LVEF ≥ 45% NT-proBNP> 400 pg/ml. The study aimed at reducing NT-proBNP from baseline at 12 weeks. Results were positive; reduced left atrial size and an improvement in NYHA class were also observed. The drug was well tolerated and had less adverse effects than the comparator valsartan.

PARAMOUNT-slides
Scott Solomon
2012-08-25

Original title: Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Patients with Heart Failure and Preserved Ejection Fraction: Primary Results from the PARAMOUNT Study

Previous article
ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using Cardio Renal Endpoints.
Next article
Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure Treatment
solaci
solaci

More articles by this author

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

solaci - 0
 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read articleMagnus Ohman2012-08-25

DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.

solaci - 0
 DeFACTO: Diagnostic Precision of CT Angiography in Determining FFR.  Read articleJames K. Min2012-08-25

Aldo-DHF: Aldosterone Receptor Blockade in Diastolic Heart Failure Treatment

solaci - 0
Editorial Comment: Fifty per cent of all HF patients involves Diastolic Heart Failure or HF with conserved ventricular function. This study aimed at evaluating...

ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using Cardio Renal Endpoints.

solaci - 0
Editorial Comment: Morbimortality in diabetic patients is still a matter of deep concern in the context of reduced cardiovascular mortality of recent years. Based...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 1

TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization.

 TRILOGY-ACS: Prasugrel vs. Clopidogrel in ACS without ST segment elevation in patients to be treated medically without revascularization. Read articleMagnus Ohman2012-08-25
solaci -
SOLACI Sessionsspot_img

Recent Articles

Complex PCI: higher ischemic and bleeding risk in contemporary practice

Dr. Andrés Rodríguez - 0
Advances in pharmacological therapies, equipment, and devices have enabled percutaneous coronary interventions (PCI) to be performed in a growing number of patients with a...

Coil embolization of segmental arteries as a spinal cord protection strategy prior to complex endovascular repair of thoracoabdominal aorta

Dr. Juan Manuel Pérez - 0
Spinal cord ischemia remains one of the most devastating complications in the repair of thoracoabdominal aneurysms, with incidences of up to 20–30% in extensive...

Mechanical thrombectomy versus anticoagulation in intermediate-risk pulmonary embolism: systematic review and meta-analysis

Dr. Juan Manuel Pérez - 0
Intermediate-risk pulmonary embolism (PE) has anticoagulation as the standard treatment, while reperfusion strategies remain a matter of debate. In this context, mechanical thrombectomy has...